Landscape of young breast cancer under 35 years in China over the past decades: a multicentre retrospective cohort study (YBCC-Catts study)
暂无分享,去创建一个
Ning Liu | Xue Wang | Changfa Xia | Yu Wang | Yixin Qi | Xiaowei Qi | Jiuda Zhao | Songqing Ye | Zixuan Lei | Jian Yue | Hairong Huang | Wanqing Chen | Peng Yuan | Yixin Qi | Xiaowei Qi | Songqing Ye | Hairong Huang | Ning Liu
[1] Fei Wang,et al. Breast Cancer Awareness and Association with Frequency of Screening Among Women — China, 2020 , 2023, China CDC weekly.
[2] R. Zheng,et al. Trends in Incidence Rates, Mortality Rates, and Age-Period-Cohort Effects of Female Breast Cancer — China, 2003–2017 , 2023, China CDC weekly.
[3] Z. Fan,et al. The outcome of neoadjuvant chemotherapy and the current trend of surgical treatment in young women with breast cancer: A multicenter real-world study (CSBrS-012) , 2023, Frontiers in Public Health.
[4] R. Gelber,et al. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Jason J. Liu,et al. Young adult cancer incidence trends in Taiwan and the U.S. from 2002 to 2016. , 2022, Cancer epidemiology.
[6] L. Testa,et al. Breast cancer trends in women younger than 40 years in Brazil. , 2022, Cancer epidemiology.
[7] Weidong Wei,et al. Comparison of the Characteristics and Prognosis Between Very Young Women and Older Women With Breast Cancer: A Multi-Institutional Report From China , 2022, Frontiers in Oncology.
[8] Lixi Li,et al. Breast Cancer in Chinese Females Aged 25 Years and Younger , 2021, Journal of oncology.
[9] A. Glas,et al. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. , 2021, The Lancet. Oncology.
[10] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[11] X. An,et al. Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial. , 2020, JAMA.
[12] M. Ceppi,et al. Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. , 2020, European journal of cancer.
[13] Jie He,et al. Cancer registration in China and its role in cancer prevention and control. , 2020, The Lancet. Oncology.
[14] A. Kwong,et al. Young onset breast cancer in Southern China - a 5-year clinico-pathological study from a multi-centre database. , 2020, Cancer treatment and research communications.
[15] Jin-hai Tang,et al. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] F. Su,et al. Introduction of a multicenter online database for non-metastatic breast cancer in China , 2020, Science China Life Sciences.
[17] Ahmedin Jemal,et al. Breast cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[18] R. Gelber,et al. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Jiong Wu,et al. Changing patterns and survival improvements of young breast cancer in China and SEER database, 1999−2017 , 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.
[20] Virginia G Kaklamani,et al. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. , 2019, The New England journal of medicine.
[21] J. Lee,et al. Insights Into Breast Cancer in the East vs the West: A Review. , 2019, JAMA oncology.
[22] Zhi-an Li,et al. Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer , 2018, Medicine.
[23] Wen-na Wang,et al. Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China , 2018, International journal of cancer.
[24] E. Winer,et al. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer , 2018, The New England journal of medicine.
[25] Virginia G Kaklamani,et al. Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.
[26] R. Gelber,et al. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] Hai-long Chen,et al. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database , 2016, PloS one.
[28] O. Olopade,et al. Effect of BRCA germline mutations on breast cancer prognosis , 2016, Medicine.
[29] Rulla M Tamimi,et al. Subtype-Dependent Relationship Between Young Age at Diagnosis and Breast Cancer Survival. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] A. Jemal,et al. Cancer statistics in China, 2015 , 2016, CA: a cancer journal for clinicians.
[31] A. Schneeweiss,et al. Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials , 2015, Breast Cancer Research and Treatment.
[32] S. Barni,et al. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial , 2015, The Lancet.
[33] I. Tengrup,et al. Age at diagnosis in relation to survival following breast cancer: a cohort study , 2015, World Journal of Surgical Oncology.
[34] P. Rosenberg,et al. A Web Tool for Age–Period–Cohort Analysis of Cancer Incidence and Mortality Rates , 2014, Cancer Epidemiology, Biomarkers & Prevention.
[35] Wanqing Chen,et al. Breast cancer in China. , 2014, The Lancet. Oncology.
[36] A. Valachis,et al. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis , 2014, Breast Cancer Research and Treatment.
[37] D. Altman,et al. Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: the POSH study. , 2013, Journal of the National Cancer Institute.
[38] A. Giuliano,et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. , 2011, JAMA.
[39] V. Cornelius,et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials , 2010, BMC Cancer.
[40] Vanja Dukic,et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer , 2009, Breast Cancer Research and Treatment.
[41] F. Holmes,et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] Umberto Veronesi,et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. , 2002, The New England journal of medicine.
[43] B. E. F. Isher,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. , 2002 .